市場調査レポート

英国の製薬・バイオテクノロジー分野における建設市場の分析

Pharmaceutical and Biotechnology Construction Sector Report - UK 2014-2018 Analysis

発行 AMA Research 商品コード 251790
出版日 ページ情報 英文 89 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。
Back to Top
英国の製薬・バイオテクノロジー分野における建設市場の分析 Pharmaceutical and Biotechnology Construction Sector Report - UK 2014-2018 Analysis
出版日: 2014年09月30日 ページ情報: 英文 89 Pages
概要

当レポートでは、英国のライフサイエンス部門で活動する建設会社とそのサプライチェーン、およびラボ・関連製品のサプライヤーに注目して調査し、製薬、医療技術、医療・産業用バイオテクノロジー部門の市場規模、主要企業および集中地域、英国における主な製造・R&D施設の概要、サイエンス・研究用の政府資源・投資資金の分析、製薬市場が直面している課題のレビューなどをまとめてお届けします。

第1章 イントロダクション

第2章 サマリー・将来予測

第3章 市場規模・概要

  • 市場定義・市場規模・市場額
    • 世界の製薬市場
    • 英国の製薬市場
    • 医療技術部門
    • 医療バイオテクノロジー部門
    • 産業バイオテクノロジー部門
    • 製薬部門
  • 製薬/バイオテクノロジーの集中地域
    • オックスフォードシャー
    • ロンドン、ケンブリッジ、スティーブニッジ
    • 製薬製造/R&Dの地理的ロケーション
  • 英国経済に対する製薬産業の価値
    • 製薬における英国の貿易
    • NHSへの医薬品の販売
  • 英国における製薬のR&D
    • サイエンスR&D用の政府資金
    • 製薬企業のR&D投資
    • R&Dパイプライン
  • 製薬産業の市場促進因子・主な課題
    • 英国におけるR&Dの将来

第4章 製薬・バイオテクノロジー部門における主要企業/大学

  • 概要
  • 製薬企業のランキング表
    • 世界
    • 英国
  • 企業プロファイル
    • Abbott Laboratories
    • AstraZeneca
      • GlaxoSmithKline (GSK)
    • Lilly
    • Merck & Co. Inc
    • Novartis
    • Pfizer
    • Roche
    • Sanofi-Aventis
    • Teva
  • その他の製薬/バイオテクノロジー企業
    • バイオテクノロジー:治療/診断
    • バイオテクノロジーR&D
    • 製薬
    • 英国サイエンスパーク

第5章 製薬・バイオテクノロジー分野における建設活動

  • 製薬分野における資本支出
  • 製薬における建設プロジェクトのパイプライン
  • 製薬産業における建設の課題
    • 建設コスト
    • 汚染/管理の問題

第6章 製薬&バイオテクノロジー分野における建設能力と供給

  • 概要
    • 特殊クリーンルームの建設、供給およびサービス
    • 建設コンサルタント&請負業者:製薬&バイオテクノロジー部門

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

INTRODUCTION and OVERVIEW

AMA Research are pleased to announce the publication of the 2nd Edition of the report 'Pharmaceutical and Biotechnology Construction Sector Report - UK 2014-2018 Analysis'. The report should be of particular interest to construction companies and their supply chains operating in the UK Life Sciences sector, and to suppliers of laboratory and allied products.

Key areas in the report:

  • Review of the pharmaceutical, medical technology, medical and industrial biotechnology sectors - market size, key players and geographical areas of concentration.
  • Overview of main manufacturing and R&D facilities in UK.
  • Review of construction activity in the sector - key projects, pipelines, players etc.
  • Analysis of Government resource and capital funding for science and research.

Areas of particular interest:

  • Major contractors, consultants, architects and product suppliers involved in the pharmaceutical and biotechnology sectors.
  • Capital Expenditure levels in the pharmaceutical/biotechnology market.
  • Construction costs and issues in the design of pharmaceutical R&D/manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design.
  • Profiles of top pharmaceutical/biotechnology companies operating in the UK - revenue, capital expenditure, key manufacturing & R&D facilities in UK, future strategy, expansion plans, forward pipelines etc.
  • Forward pipeline of capital projects in the pharmaceutical sector between 2014-2018. Review of key projects together with announcements made by leading pharmaceutical companies and universities about future expansion and investment plans.
  • Detailed analysis of pharmaceutical/biotech clusters and centres of excellence in the UK - the Oxford, Cambridge and London triangle houses the UK's largest biomedical cluster, with over 350 pharma and biotech companies linked to universities and other organisations.

Leading pharmaceutical and biotechnology companies mentioned in the report include:

AstraZeneca, Abbott Laboratories, Abcam, ABS Laboratories, ACM Global Central Lab, Allergan, Bayer CropScience, Bells Healthcare, Calea (UK), Cancer Research Technology, Cantab Biopharmaceuticals, Carbogen Amcis, Cobra Biomanufacturing, Convergence Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Huntingdon Life Sciences, Intercytex, Isis Innovation, Life Technologies, Lonza Biologics, MedImmune, Merck & Co, Mundipharma International, Norbrook Pharmaceuticals, Novartis UK, NuPharm Laboratories, Oxygen Healthcare, Pfizer, Pharmaserve Northwest, PsiOxus Therapeutics, Reading Scientific Services, Recipharm, Renovo, Roche, Sanofi Aventis, Sareum, Teva Pharmaceutical Industries, TPP Global Development, UCB Pharma, Unilever.

Leading construction companies and consultants mentioned in the report include:

ABB Group, AECOM, AMEC, Ardmac, Bassaire, BDP, Bilfinger SE, Cavendish Engineers, Clean Air Technologies, Clean Modules, Cleanroom Design & Construction, Cleanroom Solutions, ClearSphere, Enbloc Cleanrooms, Foster Wheeler, Jacobs Engineering, Kier Group, Laing O'Rourke, Lend Lease, M+W Group, Mach-Aire, Merit Merrell, Morgan Sindall, Nuvia, PM Group, Precision Cleanrooms, SDC, Shepherd Construction, Sheppard Robson, SISK Group, Validair, Wilson Mason.

Key areas covered in the report include:

OVERALL ‘PHARMACEUTICAL' MARKET

  • Global Market - analysis of size by value 2009-16, historical trends and market characteristics.
  • UK Pharmaceutical Market - by value 2011-16 - overview/ mix of key sectors - Pharmaceutical, Medical Technology, Medical Biotechnology, Industrial Biotechnology.
  • Review of each key sector - key players, sector value, number of companies/staff, key locations, overview of development pipelines etc.

KEY PLAYERS

  • Summary overview of Top 30+ companies in Pharmaceuticals / Biotechnology - major companies and geographic location of facilities in UK - Manufacturing, R&D, Packaging, Logistics.
  • Geographic review - Oxford, Cambridge, London clusters. Other key regional areas - North West, Scotland, East England, South East etc - key players, future trends.
  • R&D in UK - budgets, funding sources. Government Resource and Capital Funding for Science & Research 2011 - 2016. Research Councils (HEFCE, EPSRC, MRC etc). Key funding recipients. Overview of R&D - key players, locations, development plans.
  • Top 20 companies in UK by R&D expenditure and by Drug Pipeline 2012/13.
  • Top players - market shares. Company profiles - Key Operating & Financial Summary Data (Incl: Capital and R&D Expenditure, Locations, Pipelines, Future Strategy etc) - GSK, Astra Zeneca, Novartis, Pfizer, Eli Lilley, Merck, Abbott Laboratories, Roche, Sanofi Aventis, Teva etc.
  • Review of smaller players - pharmaceuticals / biotechnology - Capex, R&D, locations, developments etc.
  • Universities - key links/collaborations with private sector, players (Top 20 with funding levels / sources). University/industry collaborations in the Pharmaceutical Sector - Partners, Funding, Project Areas etc.
  • Spin-out companies - between 2006 and 2010 university spin-out companies floated on the stock market were worth around £3.5bn and over the over the past decade, university bioscience departments alone have generated over 200 spin-out companies - overview of key players.
  • UK Science Parks - geographical spread, size / development plans, sectors, partners - Biocity, Liverpool, West of Scotland, York, Oxford, Cambridge etc.

CONSTRUCTION ACTIVITY

  • Capital Expenditure - 2001-2012 by Value - trends, background, drivers etc.
  • Science & Research Projects - Forward Construction Pipeline 2012-2017 - Schemes, Description, Funding Source, Status, Start/Completion Dates, Capex etc.
  • Other development announcements - plans - medium/long term, new opportunities etc.
  • Construction costs - laboratories, cleanrooms, key guidelines.
  • Leading Contractors - specialist cleanroom players (construction, supply and services).
  • Key consultants / contractors - Pharmaceuticals, Biotechnology - profiles of 20+ players - sector characteristics, major strengths and weaknesses, key sectors and capabilities.

Table of Contents

1. INTRODUCTION

2. SUMMARY AND FUTURE PROSPECTS

3. MARKET SIZE AND OVERVIEW

  • 3.1. MARKET DEFINITION, SIZE AND VALUE
    • 3.1.1. Global Pharmaceutical Market
    • 3.1.2. UK Pharmaceutical Market
    • 3.1.3. Medical Technology Sector
    • 3.1.4. Medical Biotechnology Sector
    • 3.1.5. Industrial Biotechnology Sector
    • 3.1.6. Pharmaceutical Sector
  • 3.2. PHARMACEUTICAL/BIOTECHNOLOGY CLUSTERS
    • 3.2.1. Oxfordshire BioCluster
    • 3.2.2. London, Cambridge and Stevenage BioClusters
    • 3.2.3. Geographical Location of Pharmaceutical Manufacturing/R&D
  • 3.3. VALUE OF THE PHARMACEUTICAL INDUSTRY TO THE UK ECONOMY
    • 3.3.1. UK Trade in Pharmaceuticals
    • 3.3.2. Sales of Pharmaceutical Drugs to the NHS
  • 3.4. PHARMACEUTICAL R&D IN THE UK
    • 3.4.1. Government Funding for Science R&D
    • 3.4.2. Pharmaceutical Company Investment in R&D
    • 3.4.3. R&D Pipeline
  • 3.5. MARKET DRIVERS AND KEY ISSUES IN THE PHARMACEUTICAL INDUSTRY
    • 3.5.1. Future of R&D in the UK

4. LEADING COMPANIES IN THE PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS

  • 4.1. OVERVIEW
  • 4.2. PHARMACEUTICAL COMPANY LEAGUE TABLES
    • 4.2.1. Global
    • 4.2.2. UK
  • 4.3. COMPANY PROFILES
    • 4.3.1. Abbott Laboratories
    • 4.3.2. AstraZeneca
    • 4.3.3. GlaxoSmithKline (GSK)
    • 4.3.4. Lilly
    • 4.3.5. Merck & Co. Inc
    • 4.3.6. Novartis
    • 4.3.7. Pfizer
    • 4.3.8. Roche
    • 4.3.9. Sanofi-Aventis
    • 4.3.10. Teva
  • 4.4. OTHER PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES
    • 4.4.1. Biotechnology - Therapeutics/Diagnostics
    • 4.4.2. Biotechnology R&D
    • 4.4.3. Pharmaceutical
    • 4.4.4. UK Science Parks

5. CONSTRUCTION ACTIVITY IN THE PHARMACHEM AND BIOTECHNOLOGY SECTOR

  • 5.1. CAPITAL EXPENDITURE IN THE PHARMACEUTICAL SECTOR
  • 5.2. PHARMACEUTICAL CONSTRUCTION PROJECT PIPELINE
  • 5.3. CONSTRUCTION ISSUES IN THE PHARMACEUTICAL INDUSTRY
    • 5.3.1. Construction Costs
    • 5.3.2. Contamination/Control Issues

6. CONSTRUCTION CAPABILITY AND SUPPLY IN THE PHARMACEUTICAL & BIOTECHNOLOGY SECTOR

  • 6.1. OVERVIEW
    • 6.1.1. Specialist Cleanroom Construction, Supply and Services
    • 6.1.2. Construction Consultants & Contractors - Pharmaceutical & Biotechnology Sectors

TABLES AND CHARTS

  • CHART 1: TURNOVER OF THE UK PHARMACEUTICAL MARKET (£BN) 2011-2018
  • CHART 2: GLOBAL PHARMACEUTICAL MARKET BY VALUE (£BN) 2009-2016
  • TABLE 3: TURNOVER AND NO. OF COMPANIES IN THE UK LIFE SCIENCES SECTOR - SHARE BY SECTOR (PHARMACEUTICAL, MEDICAL BIOTECHNOLOGY, MEDICAL TECHNOLOGY, INDUSTRIAL BIOTECHNOLOGY) - BY % AND VALUE (£BN) 2013
  • TABLE 4: PHARMACEUTICAL & BIOTECHNOLOGY SECTOR - MAJOR COMPANIES AND GEOGRAPHICAL LOCATION OF FACILITIES IN UK - MANUFACTURING, R&D, LOGISTICS, PACKAGING
  • CHART 5: UK PHARMACEUTICAL SECTOR- DISTRIBUTION OF UK MANUFACTURING AND R&D SITES
  • CHART 6: PHARMACEUTICAL TRADE IN THE UK - MARCH 2004 - MARCH 2014 (BY VALUE (£M)
  • CHART 7: SALES OF PRESCRIPTION MEDICINES TO THE NHS - 2004 - 2013 (£M)
  • TABLE 8: GOVERNMENT RESOURCE FUNDING FOR SCIENCE & RESEARCH 2010 - 2016 (£M) - BY FUNDING PROGRAMME
  • TABLE 9: GOVERNMENT CAPITAL FUNDING FOR SCIENCE & RESEARCH 2010 - 2016 (£M) - BY FUNDING PROGRAMME
  • TABLE 10: TOP 25 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY GLOBAL R&D SPEND IN 2012/13 (£M AND % OF TURNOVER)
  • TABLE 11: TOP 20 UK PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY DRUG PIPELINE SIZE IN 2014
  • TABLE 12: MAJOR DRUG PATENT EXPIRATIONS BY PRODUCT AND COMPANY
  • TABLE 13: TOP 20 GLOBAL PHARMACEUTICAL COMPANIES BY MARKET SHARE (%) 2013
  • TABLE 14: TOP 10 PHARMACEUTICAL COMPANIES' UK MARKET SHARE (%) 2013
  • TABLE 15: ABBOTT LABORATORIES - KEY OPERATING & FINANCIAL SUMMARY DATA (TURNOVER, CAPITAL EXPEND., R&D EXPEND., KEY UK LOCATIONS, PRINCIPAL ACTIVITIES ETC)
  • TABLE 16: ASTRAZENECA - KEY OPERATING & FINANCIAL SUMMARY DATA (TURNOVER, CAPITAL EXPEND., R&D EXPEND., KEY UK LOCATIONS, PRINCIPAL ACTIVITIES ETC)
  • TABLE 17: GLAXOSMITHKLINE - KEY OPERATING & FINANCIAL SUMMARY DATA
  • TABLE 18: LILLY - KEY OPERATING & FINANCIAL SUMMARY DATA
  • TABLE 19: MERCK & CO.- KEY OPERATING & FINANCIAL SUMMARY DATA
  • TABLE 20: NOVARTIS - KEY OPERATING & FINANCIAL SUMMARY DATA
  • TABLE 21: PFIZER - KEY OPERATING & FINANCIAL SUMMARY DATA
  • TABLE 22: ROCHE - KEY OPERATING & FINANCIAL SUMMARY DATA
  • TABLE 23: SANOFI AVENTIS - KEY OPERATING & FINANCIAL SUMMARY DATA
  • TABLE 24: TEVA - KEY OPERATING & FINANCIAL SUMMARY DATA
  • TABLE 25: OTHER TOP PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES - KEY OPERATING & FINANCIAL SUMMARY DATA - REVENUES, CAPITAL EXPENDITURE, R&D EXPENDITURE, KEY UK LOCATIONS, PRINCIPAL ACTIVITIES ETC
  • TABLE 26: UK SCIENCE PARKS - SIZE, GEOGRAPHICAL SPREAD, SECTORS, KEY PARTNERS
  • CHART 27: UK PHARMACEUTICAL INDUSTRY CAPITAL EXPENDITURE - R&D AND MANUFACTURING OPERATIONS (£M) - 2002-2012
  • TABLE 28: SCIENCE & RESEARCH PROJECTS - FORWARD CONSTRUCTION PIPELINE 2014-2018
  • TABLE 29: AIRBORNE PARTICULATE CLEANLINESS CLASSES FOR CLEANROOMS (BASED ON ISO 14644-1)
Back to Top